Literature DB >> 1559895

Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990).

J P Thompson1, M J Fugent.   

Abstract

Appendicular osteosarcoma was diagnosed in 30 dogs. Fifteen dogs were treated by limb amputation alone, and 15 dogs were treated by limb amputation followed by 2 doses of cisplatin given IV approximately 2 and 7 weeks after limb removal. Mean survival time after limb amputation alone +/- SD was 190 +/- 138 days (median, 168 days); 7 dogs survived longer than 6 months, and 3 dogs survived more than 1 year. Fourteen of 15 dogs treated by amputation and administration of cisplatin survived a mean of 315 +/- 158 days (median, 290 days) after amputation, and 1 dog was still alive at 1,095 days; 13 dogs survived longer than 6 months and 5 dogs survived more than 1 year. Survival time was significantly (P less than 0.05) greater in dogs given cisplatin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559895

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  18 in total

Review 1.  Species differences in tumour responses to cancer chemotherapy.

Authors:  Jessica Lawrence; David Cameron; David Argyle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

2.  Evaluation of outcome and prognostic factors for dogs living greater than one year after diagnosis of osteosarcoma: 90 cases (1997-2008).

Authors:  William T N Culp; Francisco Olea-Popelka; Jennifer Sefton; Charles F Aldridge; Stephen J Withrow; Mary H Lafferty; Robert B Rebhun; Michael S Kent; Nicole Ehrhart
Journal:  J Am Vet Med Assoc       Date:  2014-11-15       Impact factor: 1.936

3.  Amputation and dexniguldipine as treatment for canine appendicular osteosarcoma.

Authors:  K A Hahn; A M Legendre; H M Schuller
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

4.  The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma.

Authors:  Tracy L Gieger; Julie Nettifee-Osborne; Briana Hallman; Chad Johannes; Dawn Clarke; Michael W Nolan; Laurel E Williams
Journal:  Can J Vet Res       Date:  2017-07       Impact factor: 1.310

5.  Bone tumors in a population of 400 000 insured Swedish dogs up to 10 y of age: incidence and survival.

Authors:  Agneta Egenvall; Ane Nødtvedt; Henrik von Euler
Journal:  Can J Vet Res       Date:  2007-10       Impact factor: 1.310

6.  Novel acyclic nucleotide analogues GS-343074 and GS-424044 demonstrate antiproliferative and pro-apoptotic activity in canine neoplastic cell lines.

Authors:  J A Lawrence; M K Huelsmeyer; D H Thamm; D B Tumas; G Birkus; I Kurzman; D M Vail
Journal:  Vet Comp Oncol       Date:  2013-05-15       Impact factor: 2.613

7.  Metronomic administration of lomustine following palliative radiation therapy for appendicular osteosarcoma in dogs.

Authors:  Megan E Duffy; Christie L Anderson; Kevin Choy; Janean L Fidel
Journal:  Can Vet J       Date:  2018-02       Impact factor: 1.008

8.  Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.

Authors:  Carlos O Rodriguez; Torrie A Crabbs; Dennis W Wilson; Virginia A Cannan; Katherine A Skorupski; Nancy Gordon; Nadya Koshkina; Eugenie Kleinerman; Peter M Anderson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-08       Impact factor: 2.849

Review 9.  Prognostic factors in canine appendicular osteosarcoma - a meta-analysis.

Authors:  Ilse Boerman; Gayathri T Selvarajah; Mirjam Nielen; Jolle Kirpensteijn
Journal:  BMC Vet Res       Date:  2012-05-15       Impact factor: 2.741

10.  Comparison of carboplatin and doxorubicin-based chemotherapy protocols in 470 dogs after amputation for treatment of appendicular osteosarcoma.

Authors:  L E Selmic; J H Burton; D H Thamm; S J Withrow; S E Lana
Journal:  J Vet Intern Med       Date:  2014-02-10       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.